Abstract:Objective To investigate the expression of microRNA-600(miR-600) in acute myeloid leukemia(AML) and its significance. Methods Eighty patients with AML confirmed and treated from January 2010 to June 2018 were selected as AML group,and 25 patients with non-malignant hematological diseases at the same period were served as control group.Using qRT-PCR,the expression level of miR-600 in bone marrow samples of two groups was detected,and the associations of miR-600 expression level with clinical characteristics and prognosis were analyzed in AML patients. Results The relative expression level of miR-600 in AML group was statistically lower than that in control group (P<0.01).As the cut-off value of miR-600 expression level was 0.0054,80 AML patients were divided into low expression group (n=33) and high expression group (n=47).WBC count and the incidence of FLT3/ITD mutation in low expression group were significantly higher than those in high expression group(P=0.021,P=0.044).There were no statistical differences in other clinical features and gene mutation types between two groups(all P>0.05).Follow-up for 70 patients with non-M3 AML showed that the complete remission (CR) rate in low-expression group was slightly lower than that in high-expression group(P=0.112),and the overall survival (OS) time (median OS,7 months vs 13 months,P=0.019) in low-expression group was significantly lower than that in high expression group.Multivariate analysis showed that in non-M3 AML patients,low expression of miR-600(P=0.006),old age(P=0.012)and FLT3/ITD mutation (P=0.003)were the independent influencing factors of poor prognosis. Conclusion The expression level of miR-600 in AML patients is lower than that in control group,and is related to poor clinical outcomes.